Evan Hughes

digiM's recent FDA IDIQ contract award marks a big step in advancing the role of microstructure analysis in regulatory assessment for complex generics. This partnership is set to deepen industry knowledge around product quality attributes and release mechanisms in key drug products, from injectables to implants. This recognition highlights the growing impact of microstructure tools like 3D microscopy and AI-based modeling, demonstrating how essential microstructure science is becoming within the pharmaceutical industry. https://lnkd.in/d5sj5Eds

8

Shedding some new "light" on one of our favorite summertime critters! The study utilized liquid chromatography-mass spectrometry to search for a key chemical compound. #genomics #fireflies #chromatography #massspectrometry

7

Attention researchers and scientists! Save big on your next sequencing project with Novogene's limited-time offer! Get high-quality sequencing services while saving hundreds. Send me a message or schedule a Zoom call to learn more about how we can meet your sequencing needs. Let's elevate your research together! #sequencing #research #genomics

7

Learn how choice of bandwidth can impact your fluorescence assay 🌈

1

cDNA synthesis in as little as 1 minute! Reduce the time to get your results! Invitrogen Lyo-ready SuperScript III Flash Reverse Transcriptase joins the SuperScript product family as a reverse transcriptase designed for one-step RT-qPCR and point-of-care assay development https://lnkd.in/gCBvy9CF ​

3

Happy Wednesday all! Check out this open access Cell Immunity article by Mannion et al., "A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death." Summary: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) functions as a critical stress sentinel that coordinates cell survival, inflammation, and immunogenic cell death (ICD). Although the catalytic function of RIPK1 is required to trigger cell death, its non-catalytic scaffold function mediates strong pro-survival signaling. Accordingly, cancer cells can hijack RIPK1 to block necroptosis and evade immune detection. We generated a small-molecule proteolysis-targeting chimera (PROTAC) that selectively degraded human and murine RIPK1. PROTAC-mediated depletion of RIPK1 deregulated TNFR1 and TLR3/4 signaling hubs, accentuating the output of NF-κB, MAPK, and IFN signaling. Additionally, RIPK1 degradation simultaneously promoted RIPK3 activation and necroptosis induction. We further demonstrated that RIPK1 degradation enhanced the immunostimulatory effects of radio- and immunotherapy by sensitizing cancer cells to treatment-induced TNF and interferons. This promoted ICD, antitumor immunity, and durable treatment responses. Consequently, targeting RIPK1 by PROTACs emerges as a promising approach to overcome radio- or immunotherapy resistance and enhance anticancer therapies. #drugdiscovery #immunotherapy #icd #necroptosis #celldeath #protac #inflammation #immunooncology #cancerresearch #scientificresearch

9

Mind-blowing Morphology! 🧪   Scroll through to see #iPSCs harvested in our PBS Mini from Day 1 to Day 10- no jump scares here. Behold iPSC aggregate expansion with Vertical-Wheel technology!   🔎Missed our recent Webinar where we highlighted a record cell run that yielded over 200 Billion iPSCs in one bioreactor? No worries!   👉Rewatch Spooky Good Scale-Up Success here: https://bit.ly/48gMLCK

28

Aliri scientist John Begley highlights an LC-MS biomarker assay recently developed for Coproporphyrin I and III in Human Plasma. This biomarker can be used to assess the organic anion transporting polypeptides OATB1/B3 inhibition or induction in early drug development, and eliminate the need for conducting extensive clinical drug-drug interaction (DDI) studies – saving sponsors considerable time and budget. Click here to download our poster and learn more: https://lnkd.in/eJ5HwHgv #lcms #copro #bioanalysis #Aliri #ddi #coproporphyrin

19

1 Comment

Whole genome and whole transcriptome all in one library prep also compatible with hybrid capture :)

3

Happy Friday all! Check out this open access Nature Scientific Reports article by Abali et al., "A nanowell platform to identify, sort and expand high antibody-producing cells." https://lnkd.in/gMuJNSxf Abstract: Increased use of therapeutic monoclonal antibodies and the relatively high manufacturing costs fuel the need for more efficient production methods. Here we introduce a novel, fast, robust, and safe isolation platform for screening and isolating antibody-producing cell lines using a nanowell chip and an innovative single-cell isolation method. An anti-Her2 antibody producing CHO cell pool was used as a model. The platform; (1) Assures the single-cell origin of the production clone, (2) Detects the antibody production of individual cells and (3) Isolates and expands the individual cells based on their antibody production. Using the nanowell platform we demonstrated an 1.8–4.5 increase in anti-Her2 production by CHO cells that were screened and isolated with the nanowell platform compared to CHO cells that were not screened. This increase was also shown in Fed-Batch cultures where selected high production clones showed titers of 19–100 mg/L on harvest day, while the low producer cells did not show any detectable anti-Her2 IgG production. The screening of thousands of single cells is performed under sterile conditions and the individual cells were cultured in buffers and reagents without animal components. The time required from seeding a single cell and measuring the antibody production to fully expanded clones with increased Her-2 production was 4–6 weeks. #drugdiscovery #antibodies #cancerresearch #immunotherapy #immunooncology #scientificresearch

6

The American Cytogenomics Confernce has been such a wonderful meeting to attend and it's been so valuable connecting with our cytogenetics community and learning about all the new technology and methods emerging. #Cytogenetics #Kromatid #Genomics #StructuralVariations #Karyotyping #Chromosome

43

3 Comments

The Fred Hutch Innovation Lab has conducted several benchmarking studies on single-cell technologies. Their most recent study evaluates the performance of Pipseq V4Plus T20 kit by Fluent Biosciences, which was recently acquired by Illumina. “PIPseq’s T-20 attractive feature is a low kit cost at $3600 and required one-time equipment purchase of $2500. Cost at $0.06 per cell, excluding sequencing, is competitive but reduced recovery, sequencing inefficiency and workflow demands raised this cost in our experience.” The study's conclusions align with the findings of the recently published single-cell benchmarking study I mentioned in an earlier post. Both studies demonstrate that read utilization and resulting sequencing cost should be included in any single cell technology evaluation. https://lnkd.in/eq_ncHiy

38

2 Comments

Happy Thursday all! Check out this open access Cancer Immunology, Immunotherapy review by Toledo-Stuardo, et al., "Therapeutic antibodies in oncology: an immunopharmacological overview." https://lnkd.in/g2EFFuK4 Abstract: The biotechnological development of monoclonal antibodies and their immunotherapeutic use in oncology have grown exponentially in the last decade, becoming the first-line therapy for some types of cancer. Their mechanism of action is based on the ability to regulate the immune system or by interacting with targets that are either overexpressed in tumor cells, released into the extracellular milieu or involved in processes that favor tumor growth. In addition, the intrinsic characteristics of each subclass of antibodies provide specific effector functions against the tumor by activating antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cellular phagocytosis, among other mechanisms. The rational design and engineering of monoclonal antibodies have improved their pharmacokinetic and pharmacodynamic features, thus optimizing the therapeutic regimens administered to cancer patients and improving their clinical outcomes. The selection of the immunoglobulin G subclass, modifications to its crystallizable region (Fc), and conjugation of radioactive substances or antineoplastic drugs may all improve the antitumor effects of therapeutic antibodies. This review aims to provide insights into the immunological and pharmacological aspects of therapeutic antibodies used in oncology, with a rational approach at molecular modifications that can be introduced into these biological tools, improving their efficacy in the treatment of cancer. #drugdiscovery #cancerresearch #antibodies #therapeutics #mabs #immunotherapy #immunooncology #scientificresearch

22

Looking to break into spatial biology? Our latest eBook is now available, and it's a must-read for anyone interested in this cutting-edge field. In this eBook, we explore the groundbreaking technologies that are revolutionizing spatial biology, including high-plex imaging and organ mapping antibody panels. These advancements make this field more accessible to laboratories, eliminating the need for complicated workflows and instrument upgrades. Reading this eBook gives you practical knowledge to empower your research. You'll also find an exclusive interview with one of our brilliant staff scientists, who shares insights into the revolutionary "plex" dimension and its implications for biological research. Get your copy of the eBook now! https://lnkd.in/eYB4t6GT #eBook #SpatialBiology #ThermoFisherScientific

3

It's always refreshing to be reminded of the science happening in the lab right now. Here are a few experiments currently being conducted: Residual Volatile Organic Impurities by headspace gas chromatography Drug Product Identification Testing by FT-IR Spectroscopy, NMR and 2D NMR spectroscopy Drug Product Powder X-ray Diffraction In-Process Control Reaction Completion, Purity, and Assay Analysis via UPLC Identity, Assay, and Purity by Reversed-Phase UPLC Appearance of samples Reaction product workup by flash chromatography and preparatory HPLC Biologics stability testing by size-exclusion chromatography, capillary electrophoresis-SDS and thermal shift Formulation screening Forced degradation testing In-vitro expression and screening Biologics stability screening by LCMS-qTOF Protein purification with FPLC Thanks Jake Hostetler for mentioning these last week.

20

Happy Tuesday all! Check out this open access Immunological Review by Yu et al., "Single domain antibody: Development and application in biotechnology and biopharma." Summary: Heavy-chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains-only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen-binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines. #drugdiscovery #nanobodies #cancerresearch #therapeutics #immunology #antibodies #scientificresearch

26

1 Comment

Happy Thursday all! Check out this open access Nature Leukemia review by Lei et al., "Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy." https://lnkd.in/gAWFHq-j. Abstract: Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune therapy. However, challenges remain including increasing efficacy, reducing adverse events and increasing accessibility. Use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology can effectively perform various functions such as precise integration, multi-gene editing, and genome-wide functional regulation. Additionally, CRISPR screening using large-scale guide RNA (gRNA) genetic perturbation provides an unbiased approach to understanding mechanisms underlying anti-cancer efficacy of CAR T-cells. Several emerging CRISPR tools with high specificity, controllability and efficiency are useful to modify CAR T-cells and identify new targets. In this review we summarize potential uses of the CRISPR system to improve results of CAR T-cells therapy including optimizing efficacy and safety and, developing universal CAR T-cells. We discuss challenges facing CRISPR gene editing and propose solutions highlighting future research directions in CAR T-cell therapy. #drugdiscovery #cancerresearch #crispr #tcelltherapy #immunooncology #immunotherapy #scientificresearch

35

1 Comment

🎉 Pierce BCA Protein Assay Kit Named the Most Globally Cited Protein Quantitation Kit! 🎉 According to a recent CiteAb blog post, the Pierce BCA Protein Assay Kit was the #2 most-cited life science assay kit in 2023, second only to an RNA isolation kit. This makes our BCA Protein Assay the most-cited protein quantitation kit on the market! 🏆 The Kits & Assays Market Dataset: Top 100 cited Kits & Assays in 2023 ranks leading life science assay kits and manufacturers based on citation counts. Researchers worldwide rely on the Pierce BCA Protein Assay Kit to quantify total protein samples such as lysates, serum, or protein mixtures. 🔬 Why Choose Pierce BCA? Unmatched Accuracy: 2X more accurate than Bradford Assays High Reliability: Trusted by scientists globally Versatile Applications: Ideal for various protein quantification needs 📈 Share the News: Let your proteomics customers know about this top-ranking solution, especially those using Bradford Assays or seeking new protein quantification methods. 💡 Bonus: We also offer the Pierce BCA Protein Assay Kit with our new Dilution-Free BSA Protein Standards! Explore the benefits of the most cited protein quantitation kit today: https://lnkd.in/dgzbecME ​

2